We dedicate every day to supporting our mission: Improving patients’ quality of life by delivering personal insights at the genomic level of disease.

SkylineDx is a molecular diagnostics company that serves dermatologists, pathologists and other healthcare providers across North America, from the US headquarters in San Diego, California. The US headquarters include state-of-the-art, CLIA-certified, CAP-accredited laboratory facilities that handle the specialized processes of specimen work-up and test execution. We have a dedicated support team made up of Customer Service, Medical Affairs, and Scientific Affairs.

The global headquarters are located in Rotterdam (the Netherlands) where research and development of our molecular tests are carried out. SkylineDx maintains R&D partnerships with leading health care providers and academic institutions around the world. The entrepreneurial approach of the thought leaders, combined with the scientific expertise of the SkylineDx team and global partners, positions them to solve diagnostic challenges and deliver on the promise of personalized healthcare. SkylineDx seeks to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, thereby improving patient outcomes. All R&D activities are captured in dedicated R&D Programs.

The Merlin test is a product originated from the Falcon R&D Program in Dermatology (www.falconprogram.com). Under the wings of this program, we have several active study initiatives in collaboration with an international medical field to identify solutions that address unmet needs. Aside from Merlin, the Program harbors initiatives focused on prognostic utilities in melanoma (Peregrine and Kestrel) and Squamous Cell Carcinoma (Alopex), all committed to optimize the clinical pathway of patients.

SkylineDx has two other disease specific Programs. The Panthera R&D Program in Hematology is working on initiatives for multiple myeloma and plasma cell leukemia. SKY92 is a biomarker originated from this Program and is commercially available in the US for multiple myeloma. The test to detect this biomarker measures the expression levels of myeloma-specific tumor cells and is able to determine if a patient is at high-risk for early relapse and in need of intensified treatment strategies.

Within the Delphia R&D Program in Infectious and Inflammatory Disease, we are currently collaborating with renowned institutions in London and San Diego to develop a test for the early detection of Kawasaki Disease which affects children and results in the risk of life-long cardio-vascular complications when treatment is delayed. This test is not yet commercially available.